Areas of excellence
/--/uploads/sites/4/2025/05/d5a9b33b80b48c451dfac8a5d36316605736be55.png)
/--/uploads/sites/4/2025/12/life-science.jpg)
Wallonia stands out for its deep scientific expertise and industrial strength across high-impact segments of the life sciences sector. Three key areas, in particular, offer a comprehensive value chain, from research and discovery to clinical development, manufacturing, and scale-up.
Advanced & Next-Generation Therapies
Wallonia is at the forefront of innovative therapeutics, spanning small molecules, monoclonal antibodies, antibody–drug conjugates (ADCs), and cell and gene therapies. This diversity reflects the region’s unique ability to support the full continuum of biopharmaceutical innovation. With strong science, clinical expertise, and specialized infrastructure, Wallonia’s integrated ecosystem helps biotech companies scale rapidly and deliver transformative medicines worldwide.
Medical Technology
Wallonia hosts a vibrant medtech community developing innovative diagnostic, therapeutic, and digital solutions that advance prevention, care, and patient outcomes. The region is renowned for its expertise in ophthalmology, endoscopy, and proton therapy, supported by strong engineering capabilities. It is also home to global leaders such as Johnson &
Johnson, Mölnlycke, Baxter, IBA, CooperVision, and BVI Medical, which operate major R&D and distribution hubs. A dynamic in vitro diagnostics sector, together with close collaboration between hospitals, start-ups, and established players, fuels rapid innovation and market readiness.
Nuclear Medicine
With more than 10 million patients treated each year using Belgian-produced
radioisotopes, Wallonia plays a central role in Europe’s medical isotope supply. The region’s expertise goes far beyond production, it also develops and exports world-class radiopharmaceutical equipment and systems used by hospitals and research centres worldwide. Looking ahead, Wallonia is building the foundations for tomorrow’s targeted therapies: strengthening isotope and radiopharmaceutical production while driving clinical development and the wider adoption of theranostics, supported by the expertise of its regulatory authorities and highly skilled clinical teams.
